A multiomics recovery factor predicts long COVID in the IMPACC study
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci193698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Gisela Gabernet und 56 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND Following SARS-CoV-2 infection, approximately 10%–35% of patients with COVID-19 experience long COVID (LC), in which debilitating symptoms persist for at least 3 months. Elucidating the biologic underpinnings of LC could identify therapeutic opportunities. METHODS We utilized machine learning methods on biologic analytes provided over 12 months after hospital discharge from more than 500 patients with COVID-19 in the IMPACC cohort to identify a multiomics “recovery factor,” trained on patient-reported physical function survey scores. Immune profiling data included PBMC transcriptomics, serum O-link and plasma proteomics, plasma metabolomics, and blood mass cytometry by time of flight (CyTOF) protein levels. Recovery factor scores were tested for association with LC, disease severity, clinical parameters, and immune subset frequencies. Enrichment analyses identified biologic pathways associated with recovery factor scores. RESULTS Participants with LC had lower recovery factor scores compared with recovered participants. Recovery factor scores predicted LC as early as hospital admission, irrespective of acute COVID-19 severity. Biologic characterization revealed increased inflammatory mediators, elevated signatures of heme metabolism, and decreased androgenic steroids as predictive and ongoing biomarkers of LC. Lower recovery factor scores were associated with reduced lymphocyte and increased myeloid cell frequencies. The observed signatures are consistent with persistent inflammation driving anemia and stress erythropoiesis as major biologic underpinnings of LC. CONCLUSION The multiomics recovery factor identifies patients at risk of LC early after SARS-CoV-2 infection and reveals LC biomarkers and potential treatment targets. TRIAL REGISTRATION ClinicalTrials.gov NCT04378777. FUNDING National Institute of Allergy and Infectious Diseases (NIAID), NIH (3U01AI167892-03S2, 3U01AI167892-01S2, 5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI057229-18, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07S1, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-1, 3U19AI1289130, U19AI128913-04S1, R01AI122220); NIH (UM1TR004528); and National Science Foundation (NSF) (DMS2310836).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, Connecticut, USA.
- Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
- The University of Texas at Austin, Austin, Texas, USA.
- Clinical and Data Coordinating Center (CDCC), Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Benaroya Research Institute, University of Washington, Seattle, Washington, USA.
- Baylor College of Medicine and the Center for Translational Research on Inflammatory Diseases, Houston, Texas, USA.
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NCATS NIH HHS
- National Institutes of health/National Institute of Allergy and Infectious Diseases
- National Science Foundation
- National Institutes of Health/ National INstitute of Allergy and INfectious Diseases
Zitieren
APA
Gabernet, G., Maciuch, J., Gygi, J. P., Moore, J. F., Hoch, A., Syphurs, C., Chu, T., Doni Jayavelu, N., Corry, D. B., Kheradmand, F., Baden, L. R., Sekaly, R. P., McComsey, G. A., Haddad, E. K., Cairns, C. B., Rouphael, N., Fernandez-Sesma, A., Simon, V., Metcalf, J. P., …, & Ehrlich, L. I. (2025). A multiomics recovery factor predicts long COVID in the IMPACC study. Journal of Clinical Investigation. https://doi.org/10.1172/jci193698
Vancouver
Gabernet G, Maciuch J, Gygi JP, Moore JF, Hoch A, Syphurs C, et al. A multiomics recovery factor predicts long COVID in the IMPACC study. Journal of Clinical Investigation. 2025. doi:10.1172/jci193698
BibTeX
@article{Gabernet2025,
author = {Gabernet, Gisela and Maciuch, Jessica and Gygi, Jeremy P and Moore, John F and Hoch, Annmarie and Syphurs, Caitlin and Chu, Tianyi and Doni Jayavelu, Naresh and Corry, David B and Kheradmand, Farrah and Baden, Lindsey R and Sekaly, Rafick-Pierre and McComsey, Grace A and Haddad, Elias K and Cairns, Charles B and Rouphael, Nadine and Fernandez-Sesma, Ana and Simon, Viviana and Metcalf, Jordan P and Agudelo Higuita, Nelson I and Hough, Catherine L and Messer, William B and Davis, Mark M and Nadeau, Kari C and Pulendran, Bali and Kraft, Monica and Bime, Chris and Reed, Elaine F and Schaenman, Joanna and Erle, David J and Calfee, Carolyn S and Atkinson, Mark A and Brakenridge, Scott C and Melamed, Esther and Shaw, Albert C and Hafler, David A and Augustine, Alison D and Becker, Patrice M and Ozonoff, Al and Bosinger, Steven E and Eckalbar, Walter and Maecker, Holden T and Kim-Schulze, Seunghee and Steen, Hanno and Krammer, Florian and Westendorf, Kerstin and IMPACC Network, IMPACC Network and Peters, Bjoern and Fourati, Slim and Altman, Matthew C and Levy, Ofer and Smolen, Kinga K and Montgomery, Ruth R and Diray-Arce, Joann and Kleinstein, Steven H and Guan, Leying and Ehrlich, Lauren Ir},
title = {A multiomics recovery factor predicts long COVID in the IMPACC study},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci193698}
}
EUVIMED